Navigation Links
Gen-Probe Reports Strong Financial Results for First Quarter 2008, Raises Full-Year Guidance
Date:4/28/2008

million in the prior year period, an increase of 4% that resulted primarily from two factors: increased reimbursement from Novartis of shared development expenses in the companies' blood screening collaboration; and increased reimbursement from 3M related to the companies' collaboration to develop rapid tests for healthcare-associated infections. These increases were partially offset by a reduction in funds received from the U.S. Department of Defense for prostate cancer research.

Royalty and license revenues for the first quarter of 2008 were $18.6 million, compared to $11.5 million in the prior year period. As previously discussed, this increase resulted primarily from $16.4 million of revenue from Bayer, which represents the third and final payment due in connection with the 2006 settlement of the companies' patent infringement litigation. In the prior year period, royalty and license revenues included $10.3 million from Bayer.

Gross margin on product sales in the first quarter of 2008 was 67.8%, compared to 66.5% in the prior year period. This improvement resulted primarily from increased sales of the APTIMA Combo 2 assay and from commercial pricing of the PROCLEIX WNV assay on the TIGRIS system in the United States. These benefits were partially offset by increased instrument sales, as described above.

Research and development (R&D) expenses in the first quarter of 2008 were $23.1 million, compared to $20.3 million in the prior year period, an increase of 14%. This increase resulted primarily from costs associated with key development programs such as the post-marketing studies of the PROCLEIX ULTRIO assay in the United States, the investigational APTIMA(R) human papillomavirus (HPV) assay, and Gen-Probe's fully automated instrument system for low- and mid-volume labs, known as PANTHER.

Marketing and sales expenses in the first quarter of 2008 were $11.9 million, compared to $9.5 million in the prior year period, an increase of 25%
'/>"/>

SOURCE Gen-Probe Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related biology technology :

1. Gen-Probe to Webcast Presentation at Morgan Stanley Global Healthcare Unplugged Conference
2. Gen-Probe to Webcast Presentations at Lehman and Cowen Healthcare Conferences
3. Gen-Probe Reports Strong Financial Results for Fourth Quarter and Full Year 2007
4. Carl Hull Named President and Chief Operating Officer of Gen-Probe
5. Gen-Probe Announces Webcast of Fourth Quarter and Full Year 2007 Earnings Conference Call
6. Gen-Probe to Webcast Three Upcoming Presentations
7. Gen-Probe Reports Strong Financial Results for Third Quarter 2007, Raises Full-Year Guidance for Earnings Per Share and Total Revenues
8. Gen-Probe to Webcast Presentation at Bank of Americas 37th Annual Investment Conference
9. Simcere Pharmaceutical Group Reports Proposed Private Sale of Ordinary Shares by Existing Shareholder
10. CV Therapeutics Reports 2008 First Quarter Financial Results
11. Caliper Life Sciences Reports West Coast Consolidation of Operations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... 29, 2015  AsureQuality and Ubiquitome have agreed ... applications in food and primary production sectors. The ... PCR device, the Freedom4. AsureQuality provides ... the supermarket shelf for producers, processors and Competent ... animal disease control and pest management and surveillance ...
(Date:7/29/2015)... 2015  AmnioChor Inc., an early stage biotech startup ... to announce that the Musculoskeletal Transplant Foundation of ... in their seed round of development of the proprietary ... AmnioChor,s technology allows cryopreservation of the ... cells living within those tissues. Amnion is a well-established ...
(Date:7/29/2015)... (PRWEB) , ... July 29, 2015 , ... The third ... of combination products , in particular, drug/device combinations. The current system received a ... the Initiative for Patient Centered Innovation (iPCI) of Fairleigh Dickinson University’s ( ...
(Date:7/29/2015)... ... July 29, 2015 , ... CSSi LifeSciences™ formalized ... specializing in Clinical Trial Management. CSSi LifeSciences is specialized in strategic, marketing, and ... PRC Clinical is focused on Clinical Trial Management, Clinical Site Monitoring, and Clinical ...
Breaking Biology Technology:AsureQuality and Ubiquitome Partner on Applications for Mobile Molecular Food Safety Testing 2The Musculoskeletal Transplant Foundation Agrees to Invest in AmnioChor 2Third Medical Innovation Impact Index Issued by Fairleigh Dickinson University’s Initiative for Patient-Centered Innovation (iPCI) 2Third Medical Innovation Impact Index Issued by Fairleigh Dickinson University’s Initiative for Patient-Centered Innovation (iPCI) 3CSSi LifeSciences And PRC Clinical Join Forces To Offer Extended Clinical Trial Services 2CSSi LifeSciences And PRC Clinical Join Forces To Offer Extended Clinical Trial Services 3
... 14 TorreyPines Therapeutics,Inc. (Nasdaq: TPTX ) today ... 2007. For the three-month period, the Company posted,revenue of ... Cash and cash,equivalents totaled $39.7 million at September 30, ... three priority product,candidates and most notably, after the quarter ...
... MELBOURNE, Australia, Nov. 14 Swiss experts have,abandoned ... (TST) favouring the,use of interferon-a release assays such ... (TB) infection prior to initiating,biological treatments (such as ... of the Swiss Medical Weekly, experts,advocate the use ...
... Calif., Nov. 13 AMDL, Inc. (Amex:,ADL) reported today ... Securities and,Exchange Commission indicating that its Form 10-QSB for ... filed by November 14, 2007. However,AMDL expects to file ... time,allotted by the Rules. Gary L. Dreher, President, stated: ...
Cached Biology Technology:TorreyPines Therapeutics Reports Third Quarter 2007 Results 2TorreyPines Therapeutics Reports Third Quarter 2007 Results 3TorreyPines Therapeutics Reports Third Quarter 2007 Results 4TorreyPines Therapeutics Reports Third Quarter 2007 Results 5TorreyPines Therapeutics Reports Third Quarter 2007 Results 6Swiss Experts Recommend QuantiFERON(R)-TB Gold for Tuberculosis Infection Screening Prior to Initiating anti-TNF-a Therapy 2Swiss Experts Recommend QuantiFERON(R)-TB Gold for Tuberculosis Infection Screening Prior to Initiating anti-TNF-a Therapy 3AMDL Announces Filing of Extension on Third Quarter 2007 Form 10-QSB 2
(Date:7/31/2015)... , Chine, 31 juillet 2015 La ... www.icg-10.org ) sera organisée par le BGI du ... Shenzhen en Chine. La ... son inauguration en 2006, l,ICG est devenue l,une ... le domaine des « omiques » et c,est aussi la ...
(Date:7/31/2015)... , 31 de julio de 2015 La ... ) se celebrará por medio de BGI del 22 al 25 ... . Este año, la conferencia celebra su ... se ha convertido en una de las reuniones anuales más ... una de las reuniones más dinámicas, entusiastas y mejores a ...
(Date:7/31/2015)... 31. Juli 2015 Die 10. internationale Konferenz zu ... veranstaltet und findet vom 22. bis 25. Oktober ... statt. Die Konferenz feiert in ... 2006 ist die ICG weltweit zu einem der ... ist eines der dynamischsten, enthusiastischsten und angenehmsten wissenschaftlichen ...
Breaking Biology News(10 mins):La 10e International Conference on Genomics (ICG-10) doit s'ouvrir en octobre 2La 10e International Conference on Genomics (ICG-10) doit s'ouvrir en octobre 3La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 2La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 3Die 10. internationale Konferenz zu Genomik (ICG-10) beginnt im Oktober 2Die 10. internationale Konferenz zu Genomik (ICG-10) beginnt im Oktober 3
... BIO-key International, Inc. (OTC Bulletin Board: BKYI), a leader in ... ended March 31, 2010 . For clarity and consistency, the data ... Biometrics Division for such period.  The Company completed the sale of its ... , , ...
... have discovered that cheese can help preserve and enhance ... a carrier for probiotic bacteria. The research, published in ... daily consumption of probiotic cheese helps to tackle age-related ... the proportion of aged individuals in modern society makes ...
... 22q.11 deletion syndrome have identified key proteins that act ... essential to life; in animal studies, embryos without the ... of gestation. Although the findings do not ... shed light on the biological events that give rise ...
Cached Biology News:BIO-key(R) Reports First Quarter 2010 Financial Results 2BIO-key(R) Reports First Quarter 2010 Financial Results 3BIO-key(R) Reports First Quarter 2010 Financial Results 4BIO-key(R) Reports First Quarter 2010 Financial Results 5Cheese found to improve the immune response of the elderly 2Study finds protein that plays key role in early embryonic development 2
Mouse monoclonal antibody raised against a partial recombinant SCARB2. NCBI Entrez Gene ID = SCARB2...
Mouse monoclonal antibody raised against a partial recombinant FAAH. NCBI Entrez Gene ID = FAAH...
Alpha-2-antiplasmin precursor (Alpha-2-plasmin inhibitor) (Alpha-2-PI) (Alpha-2-AP). [Source:Uniprot/SWISSPROT;Acc:P08697] Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....
Mouse polyclonal antibody raised against a partial recombinant CSRP3. NCBI Entrez Gene ID = 8048...
Biology Products: